This article's lead is ready for translation. Click for more information.

Belatacept

From WikiProjectMed
Jump to navigation Jump to search
Belatacept
Names
Trade namesNulojix
Clinical data
Drug classT cell activation inhibitor[1]
Main usesKidney transplant[2]
Side effectsLow red blood cells, diarrhea, urinary tract infection, swelling, constipation, fever, cough, nausea, low or high potassium[2]
Pregnancy
category
  • AU: C
  • US: N (Not classified yet)
Routes of
use		Intravenous
Typical dose5 to 10 mg/kg[3]
External links
AHFS/Drugs.comMonograph
MedlinePlusa606016
Legal
License data
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only

Belatacept, sold under the brand name Nulojix, is a medication used to prevent rejection following a kidney transplant.[2] It is used with corticosteroids and mycophenolic acid.[3] Use in the United Kingdom is not generally recommended.[1] It is given by injection into a vein.[3]

Common side effects include low red blood cells, diarrhea, urinary tract infection, swelling, constipation, fever, cough, nausea, and low or high potassium.[2] Other side effects may include infections, cancer, and posttransplant lymphoproliferative disorder.[4] It is a recombinant fusion protein which acts as a T cell activation inhibitor.[1][4]

Belatacept was approved for medical use in the United States and Europe in 2011.[2][3] In the United Kingdom 250 mg costs the NHS about £355 as of 2021.[1] This amount in the United States is about 930 USD.[5]

Medical uses

Dosage

It is initially given at a dose of 10 mg/kg at the time of surgery.[3] Further doses are than given at days 5, 14, and 28 and at 8 and 12 weeks.[3] Further doses of 5 mg/kg are than given every 4 weeks.[3]

Mechanism of action

Mechanism of belatacept[6]

In terms of the mode of action we find that Belatacept binds to CD80 and CD86 receptors which are on antigen-presenting cells, to therefore stop selective T-cell stimulation of lymphocytes[6]

Chemistry

It is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It differs from abatacept (Orencia) by only two amino acids.

References

  1. ↑ 1.0 1.1 1.2 1.3 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 893. ISBN 978-0857114105.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 "DailyMed - NULOJIX- belatacept injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 25 March 2021. Retrieved 8 January 2022.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 "Nulojix". Archived from the original on 22 June 2021. Retrieved 8 January 2022.
  4. ↑ 4.0 4.1 "Belatacept Monograph for Professionals". Drugs.com. Archived from the original on 24 November 2020. Retrieved 8 January 2022.
  5. ↑ "Belatacept Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 8 January 2022.
  6. ↑ 6.0 6.1 Kumar, Jayant; Reccia, Isabella; Virdis, Francesco; Podda, Mauro; Sharma, Ajay Kumar; Halawa, Ahmed (18 March 2021). "Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review". World Journal of Transplantation. 11 (3): 70–86. doi:10.5500/wjt.v11.i3.70. Archived from the original on 18 April 2024. Retrieved 21 June 2024.

External links

External sites:
Identifiers:

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help MDWiki by expanding it.

Retrieved from "https://mdwiki.org/w/index.php?title=Belatacept&oldid=1458983"